A multicenter study to assess effects of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Latest Information Update: 20 Apr 2022
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Apr 2022 New trial record
- 01 Mar 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia